Development of radiosensitized nanoparticles for all cancers using simple and innovative surface-modified DDS

使用简单且创新的表面改性 DDS 开发针对所有癌症的放射增敏纳米颗粒

• 批准号: 22K07771
• 负责人: 赤坂 浩亮
• 金额: $ 2.66万
• 依托单位: Kobe University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2022
• 资助国家: 日本
• 起止时间: 2022-04-01 至 2025-03-31
• 项目状态: 未结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22K07771/
• 关键词: ナノ粒子; 放射線治療; 過酸化チタンナノ粒子; DDS; 放射線; 放射線増感; 金属ナノ粒子

金属ナノ粒子を用いた放射線増感剤の研究には、腫瘍への送達性と生体安全性の課題が常に付きまとうが、我々のグループは先行研究において、メルボルン大学のFrank Caruso教授のグループが開発したAPS （Antibody Polyphenol System)と呼ばれる金属ナノ粒子を抗体でコーティングする技術を応用することで、前述の課題の解決に成功した。世界最大級のROS産生能を有する過酸化チタンナノ粒子と、抗体コーティング技術であるAPSの融合は、これまでに類を見ない革新的ながん治療の開発に繋がる。本申請において、我々はAPS-過酸化チタンナノ粒子の臨床応用に向け、①多種の抗体に対応したAPSの合成、②各種がん腫瘍への特異的集積性の評価、③放射線増感効果の確認、④生体安全性の確認、の具体的な４課題を通し、First-in-Humanの臨床試験を見据えた非臨床試験の準備に取り組む。当該年度においては、抗CD44抗体を修飾した過酸化チタンナノ粒子を用いて、MDA-MB-231細胞、BT-474細胞、及びMIAPaCa2細胞に対する特異的集積性、放射線併用時の抗腫瘍効果、及びライソソームへの取り込み確認の検討を実施した。、

The study of the safety of healthy animals by the use of radioactive materials, the safety of animals, the study of health care, the study of health care, the use of APS (Antibody Polyphenol System), the application of antibodies to metal particles, the use of anti-virus antibodies, the use of health care equipment, the use of health care tools, the use of anti-virus antibodies, the use of anti-virus antibodies, and the use of health care tools. The solution to the above-mentioned problem is successful. The world's largest ROS producer has the ability to acidify particles, antibodies, technology, APS fusion, and innovative medical treatment. In this application, we apply for APS- Acidizing Assay in the particle bed, synthesis of more than 1 antibody in the bed, integration of 2 specific antibodies, 3 radiological response confirmation, 4-biosafety confirmation, specific information on 4 topics, and First-in-Human laboratory tests on the basis of the non-laboratory laboratory program. In the current year, the anti-CD44 antibody test has been used to acidify the concentration of antigens, MDA-MB-231 cells, BT-474 cells, and MIAPaCa2 cells, as well as the use of time-dependent antigens, and to determine the effectiveness of the test. 、

项目成果

Clinical log file analysis for assessing the tracking accuracy of stereotactic spinal radiosurgery in prone position

用于评估俯卧位立体定向脊柱放射外科跟踪准确性的临床日志文件分析

• 发表时间: 2022
• 作者: 5.Kazufusa Mizonobe;Kazuyuki Uehara;Hiroaki Akasaka;Yuya Oki;Syuhei Tamura;Yoshiki Munetomo;Hiroshi Mayahara
• 通讯作者: Hiroshi Mayahara

Safety and Efficacy of Transvenous Fiducial Marker Placement for Stereotactic Body Radiotherapy of Malignant Lung Tumors

经静脉基准标记放置用于肺癌立体定向放射治疗的安全性和有效性

• 发表时间: 2022
• 作者: 2.Haruna Kawaguchi;Jun Ishida;Chihiro Shindo;Hiroki Horinouchi;Kazuki Terashima;Hiroshi Mayahara;Hiroaki Akasaka;Kazufusa Mizonobe;Masahiko Fujii
• 通讯作者: Masahiko Fujii

Development of Stoichiometric calibration method for MVCT to MD table on Tomotherapy

断层放射治疗中 MVCT 至 MD 表的化学计量校准方法的开发

• 发表时间: 2022
• 作者: 4.Shogo Tsunemine;Shuichi Ozawa;Minoru Nakao;Hideharu Miura;Daisuke Kawahara;Akito Saito;Yasuhiko Onishi;Takashi Onishi;Mamoru Ichiki;Satoru Sugimoto;Tatsuya Inoue;Hiroaki Akasaka;Yuya Oki;Hidetoshi Yamasaki;Tsutomu Maruta;Yuji Murakami and
• 通讯作者: Yuji Murakami and

Association of Fiducial Marker Position with Target Volume in Stereotactic Lung Irradiation: A Cross-Sectional Study

立体定向肺部照射中基准标记位置与目标体积的关联：横断面研究

• 发表时间: 2022
• 作者: 1.Hiroaki Akasaka;Kazufusa Mizonobe;Yuya Oki;Kazuyuki Uehara;Shuhei Tamura;Yoshiki Munetomo;Aya Harada;Masao Nakayama;Haruna Kawaguchi and Hiroshi Mayahara
• 通讯作者: Haruna Kawaguchi and Hiroshi Mayahara

The position variation between fiducial marker and tumor according to respiratory motion of 250 patients treated by CyberKnife

250例射波刀治疗患者呼吸运动引起的基准标记与肿瘤之间的位置变化

• 发表时间: 2022
• 作者: 3.Hiroaki Akasaka;Kazufusa Mizonobe;Yuya Oki;Kazuyuki Uehara;Shuhei Tamura;Yoshiki Munetomo;Takeaki Ishihara;Haruna Kawaguchi;Jun Ishida and Hiroshi Mayahara
• 通讯作者: Jun Ishida and Hiroshi Mayahara